Form 4: Vivani Medical Executive Le Truc Reports Stock Option and RSU Grants

Chief Operations Officer Le Truc of Vivani Medical, Inc. reports the acquisition of stock options and restricted stock units (RSUs) on May 12, 2025.

Summary

• Le Truc, Chief Operations Officer of Vivani Medical, Inc., filed a Form 4 on May 14, 2025, reporting transactions related to the company's stock.
• On May 12, 2025, Le Truc acquired 160,000 common stock options with an exercise price of $1.03.
• These options vest 25% after one year and then monthly over the following 36 months, contingent upon continued service.
• Additionally, Le Truc acquired 80,000 performance-based RSUs, each representing one share of Vivani common stock.
• These RSUs vest in three stages based on the stock price closing at or above $3.15 for three consecutive days, with subsequent vesting tranches occurring one and two years after the initial market condition is met, also contingent upon continued service.
• If the stock price does not reach the $3.15 threshold within four years, the RSUs will expire.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The performance-based RSUs suggest a positive outlook, but the risk of the RSUs expiring if the stock price target is not met tempers the overall sentiment.

Positives

• The grant of stock options and RSUs to the COO aligns their interests with those of the shareholders.
• The performance-based vesting of the RSUs incentivizes the COO to drive the company's stock price higher.
• The vesting schedule encourages long-term commitment from the COO.

Risks

• The performance-based RSUs may expire if the stock price does not reach $3.15 within four years.
• The vesting of both the stock options and RSUs is contingent upon the COO's continued service, creating a potential risk if the COO leaves the company.

Future Outlook

The vesting of the RSUs is tied to the company's stock performance, suggesting an expectation of future growth and value creation.

Industry Context

Granting stock options and RSUs is a common practice in the biotech industry to incentivize executives and align their interests with shareholders. The performance-based vesting of the RSUs is a mechanism to ensure that executives are rewarded for achieving specific milestones.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the pharmaceutical and biotech industries.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation to incentivize their executives.
• The vesting schedules and performance-based criteria are generally aligned with industry norms, aiming to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with their own.
• Employees may be motivated by the potential for the company's stock price to increase, triggering the vesting of the performance-based RSUs.

Key Dates

Keywords

Form 4, Vivani Medical, VANI, Le Truc, Stock Options, RSUs, Restricted Stock Units, Beneficial Ownership, Chief Operations Officer